← Back to Patent Explorer
US6140111A Expired / Lapsed US ⏱️ 0.0 years remaining

Retroviral gene therapy vectors and therapeutic methods based thereon

Assignee: Cell Genesys Inc
•
Filing: 1995-06-07
•
Granted: 2000-10-31
•
Expires: 2015-06-07
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Retroviral vectors are disclosed which include an insertion site for genes of interest and are capable of expressing high levels of the protein derived from the genes of interest in a wide variety of transfected cell types. Also disclosed are retroviral vectors lacking a selectable marker, thus rendering them suitable for human gene therapy in the treatment of a variety of disease states without the co-expression of a marker product, such as an antibiotic. These retroviral vectors are especially suited for use in certain packaging cell lines.

Inventors

  • 👤 Isabelle Riviere
  • 👤 Lawrence K. Cohen
  • 👤 Brad Guild
  • 👤 Lori F. Rafield
  • 👤 Paul Robbins
  • 👤 Richard C. Mulligan

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-03 01:06
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/36; A61K38/37; A61K38/43; A61K38/46; A61K38/48; A61K38/49; A61K38/50; A61L; A61L27/00; A61L27/36; A61L27/38; A61L33/00; A61L33/18; C12N5/00; C12N5/06; C12N5/0602; C12N5/069; A61K35/00; A61K35/12; A61K2035/124; A61K48/00; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/13011; C12N2740/13041; C12N2740/13043

Claims Analysis

Total Claims: 4
Claim 1
Independent Claim 115 words
A recombinant retroviral vector, said vector comprising in operable combination a) 5' R and U5 sequences, and 3' U3 and R sequences derived from the LTRs of a retrovirus of interest; b) a Psi packaging site recognized by an amphotropic retrovirus; c) an insertion site for a gene of interest located 3' to said U5 sequence; and d) a splice acceptor site located 3' to said Psi packaging site, wherein said splice acceptor site is a splice acceptor site necessary for the generation of the env mRNA of a wild type retrovirus; wherein said recombinant retroviral vector does not contain a complete gag, pol, or env gene, and does not express a functional marker gene.
Claim 2
Dependent Claim 115 words
A recombinant retroviral vector, said vector comprising in operable combination a) 5' R and U5 sequences, and 3' U3 and R sequences derived from the LTRs of a retrovirus of interest; b) a Psi packaging site recognized by an amphotropic retrovirus; c) an insertion site for a gene of interest located 3' to said U5 sequence; and d) a splice acceptor site located 3' to said Psi packaging site, wherein said splice acceptor site is a splice acceptor site necessary for the generation of the env mRNA of a wild type retrovirus; wherein said recombinant retroviral vector does not contain a complete gag, pol, or env gene, and does not express a functional marker gene.
Claim 3
Dependent Claim 32 words
The recombinant retroviral vector according to claim 1 further comprising a portion of the gag coding sequence; a splice donor site and a splice acceptor site located upstream from said insertion site.
Claim 4
Dependent Claim 37 words
The recombinant retroviral vector according to claim 2 further comprising a gag transcriptional promoter functionally positioned such that a transcript of a nucleotide sequence inserted into said insertion site is transcribed with a 5' gag untranslated region.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2003-10-31 2004-05-01 2004-10-31 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2007-10-31 2008-05-01 2008-10-31 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2011-10-31 2012-05-01 2012-10-31 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag